Frontier Medicines’ Post

Check out our article about overcoming the development challenges of PEGylated therapeutics 👇🏻

Purchase of a pre-clinical novel antibiotic class active against Gram-negative pathogens.

Researchers, how would you propose to progress drug delivery systems for the posterior inner eye segment? Your solutions should ensure sustained release over at least three months for diverse therapeutics ranging from low molecular weight compounds to complex molecules. Learn more on our open science platform #opnMe: https://lnkd.in/gEDjfkdd

🌟 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗨𝗺𝗮𝗯𝘀𝗗𝗕 𝗼𝗻 𝗔𝗯𝗶𝗻𝘃𝗶𝘃𝗼, 𝗮 𝗕𝗶𝗼𝗶𝗻𝘁𝗿𝗼𝗻 𝗯𝗿𝗮𝗻𝗱 🌟 UmabsDB is a leading database for antibody therapeutics, providing detailed information on the development, origin, target, indication, sequence, patent, and clinical status of antibodies. Abinvivo is a Biointron brand that provides catalog products for in vivo research with the ease of online ordering. Simply create an account on the Abinvivo website and navigate to UmabsDB in the menu bar. Use the database for free by registering now–dive into the wealth of information UmabsDB provides! Register now here 👉 https://lnkd.in/e_bfaACy #Biointron #Biotech #Supplier #Antibody #DrugDevelopment #Database

Thanks to everyone who joined and asked questions at our seminar with N=1 Collaborative yesterday! Our Chief Technology Officer, David Butler, spoke on a panel of experts about "Control of regulatory starting material quality for oligonucleotide therapeutics". During the talk, David provided insights into the synthesis of phosphoramidites, a systematic approach to categorizing phosphoramidite impurities, and analytical techniques for purity and impurities characterization and measurement of amidites used in N=1 oligonucleotides. Did you miss it? Don't worry, you can catch up with the recording on-demand via the link below. 👇 https://loom.ly/4n4G4Kw #Oligonucleotides #PharmaEvent #CDMO

Testing efficacy in multiple #ALS model lines can assure efficacy in clinical trials. We discussed how patient factors are challenging scientists from reaching markets? https://lnkd.in/gFpERB4T

🔍 Need to accelerate your drug discovery program? Let us help you. BPS Bioscience Inc. offer screening services to quickly identify potential therapeutics, predict potency, and narrow down large pools of candidates to much smaller ones. Additionally, cell-based screening services are also available for a more comprehensive view of the biological context and resulting cellular responses. Follow the link for more information 👇 https://lnkd.in/ei9wwpMA #DrugDiscovery #Bioscience

FibroBiologics is set to join the Russell 2000® Index effective July 1, 2024, according to a preliminary list of additions. This milestone reflects our growth and commitment to developing novel therapeutics using fibroblasts. Joining the #Russell2000 marks a significant step in increasing our visibility in the investment community and enhancing shareholder value. For more: https://bit.ly/4cHC6ST #Biotechnology #InvestmentGrowth

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

Providing a snapshot of FDB's PEGylation experience and capacity - from PD to commercial scale.